Parathyroidectomy and Mobility Study

Inclusion Criteria

• •Inclusion:
• •Age ≥ 60 years;
• •Biochemical diagnosis of hypercalcemic (corrected serum calcium \>10.2 mg/dL or ionized serum calcium \>1.31 mmol/dL or 5.2 mg/dL on at least one serum sample) primary hyperparathyroidism as determined by board-certified endocrinologist or endocrine surgeon;
• •Undergoing parathyroidectomy at UF Health;
• •Willing and able to give informed consent.
• •Exclusion:
• •Failure to provide informed consent;
• •Biochemical diagnosis of eucalcemic primary hyperparathyroidism (corrected serum calcium ≤10.2 mg/dL or ionized serum calcium ≤1.31 mmol/dL or 5.2 mg/dL on at least one serum sample);
• •Elected not to undergo parathyroidectomy at UF Health;
• •Major surgery as deemed by principal investigator or hip/knee replacement in the past 6 months;
• •Fractures to the hands, arms or legs within the last 6 months;
• •Traumatic accident (i.e. motor vehicle collision, fall from elevation, etc.) resulting in orthopedic trauma or requiring prolonged immobilization (\>2 weeks) within the last 6 months;
• •Blood transfusion within the past 3 months;
• •Self-reported myocardial infarction, cerebrovascular accident, or unstable angina within the past 6 months;
• •NYHA Class 3 or 4 congestive heart failure;
• •Major psychiatric disorder;
• •Cancer requiring treatment in the past 1 year (including metastatic cancer), except for locally treated non-melanoma skin cancers or cancers that have clearly been cured or in the opinion of the investigator carry an excellent prognosis (e.g., Stage 1 cervical cancer);
• •Renal failure requiring hemodialysis or peritoneal dialysis
• •Use of bone-modifying therapies (alendronate \[Fosamax\], zoledronic acid \[Reclast\], denosumab \[Prolia or Xgeva\], or romosozumab \[Evenity\]) within 1 month of planned surgery
• •Planning to permanently leave the area within 3 months of parathyroidectomy;
• •Vision or hearing impairment - defined as unable to read or listen/follow instructions despite the use of maximal assistive devices (i.e. contact lenses, glasses, hearing aids, etc.)
• •Participating in another clinical trial or has received an investigational product within 30 days prior to screening/enrollment.